
MAIA
MAIA Biotechnology
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 0
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About MAIA
Maia Biotechnology, Inc.
A clinical stage biotechnology company that developing therapies for non-small cell lung cancer
444 West Lake Street, Suite 1700, Chicago, IL 60606
--
MAIA Biotechnology, Inc., was incorporated in Delaware on August 3, 2018. The company is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The company's main asset, THIO, is an investigational dual mechanism of action drug candidate that combines telomere targeting and immunogenicity. THIO is a telomere targeting agent currently in clinical development to evaluate its activity in NSCLC. THIO is being developed as a second-line or follow-up treatment line for NSCLC for patients whose treatment progresses beyond the existing standard regimen of checkpoint inhibitors. The company's THIO project has led to the company's second-generation telomere targeting agent development pipeline. The company has launched an early stage research and discovery program aimed at identifying new compounds that can act through an active mechanism similar to THIO, such as targeting and modifying the telomere structure of cancer cells through telomerase activity inherent in cancer cells. The company's current pipeline of second-generation potential telomeric targeting agents includes five compounds that have been successfully tested for in vitro inhibition in five cancer models.
Company Financials
EPS
MAIA has released its 2024 Q4 earnings. EPS was reported at -0.32, versus the expected -0.35, beating expectations. The chart below visualizes how MAIA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available